<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00525668</url>
  </required_header>
  <id_info>
    <org_study_id>2006-006323-39</org_study_id>
    <nct_id>NCT00525668</nct_id>
  </id_info>
  <brief_title>Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study)</brief_title>
  <acronym>SuniMS</acronym>
  <official_title>Sunphenon EGCg (Epigallocatechin-gallate) in Relapsing-remitting Multiple Sclerosis (SuniMS Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis:

      Sunphenon, a green tea extract containing 95% egcg, given daily as oral medication over a
      period of 18 months has anti-inflammatory and neuroprotective properties in patients with
      relapsing-remitting multiple sclerosis as assessed by magnetic resonance imaging and clinical
      examination (EDSS and MSFC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multicentric, national study investigates the efficacy and safety of EGCG in patients
      with relapsing-remitting multiple sclerosis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of new T2 lesions on brain MRI performed after 18 months of Sunphenon treatment compared to baseline MRI in the verum arm versus placebo</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>development of brain atrophy under treatment with EGCG vs. placebo</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Relapsing-remitting Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>verum</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sunphenon plus glatiramer acetate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>placebo plus glatiramer acetate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epigallocatechin-gallate (Sunphenon)</intervention_name>
    <description>200 mg twice daily, after 3 months 400 mg twice daily</description>
    <arm_group_label>verum</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>2 placebo capsules twice daily, after 3 months 4 placebo capsules twice daily</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male and female subjects age 18 to 60

          -  relapsing-remitting course of MS

          -  stable treatment with glatiramer acetate at least 6 months prior to inclusion

        Exclusion Criteria:

          -  primary or secondary progressive forms of MS

          -  clinically relevant heart, lung, liver, kidney diseases

          -  regular hepatotoxic co-medication

          -  drug addiction

          -  alcohol abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Judith Bellmann-Strobl, Dr., MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Experimental and Clinical Research Center, Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Friedemann Paul, Prof. , MD</last_name>
    <role>Study Director</role>
    <affiliation>NeuroCure Clinical Research Center, Charit√© University, Berlin, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NeuroCure Clinical Research Center, Charite University, Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Outpatient Clinic for Neuroimmunology at the ECRC, Charite University, Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.ncrc.de</url>
    <description>Homepage of the NeuroCure Clinical Research Center</description>
  </link>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 4, 2007</study_first_submitted>
  <study_first_submitted_qc>September 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 6, 2007</study_first_posted>
  <last_update_submitted>December 21, 2017</last_update_submitted>
  <last_update_submitted_qc>December 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Friedemann Paul</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>multiple sclerosis</keyword>
  <keyword>inflammation</keyword>
  <keyword>neurodegeneration</keyword>
  <keyword>neuroprotection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glatiramer Acetate</mesh_term>
    <mesh_term>Epigallocatechin gallate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

